L.Z. AFANDIEVA, D.D. GAYNETDINOVA

 Kazan State Medical University, Kazan

Contact details:

Afandieva L.Z. — PhD (medicine), Assistant Lecturer of the Department of Neurology, Neurosurgery and Medical Genetics

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-917-294-18-93, e-mail: lisenok_af@list.ru

Cerebral palsy (CP) is a group of persistent motor and postural disorders that cause activity limitations, which are explained by non-progressive disorders in the developing brain [1]. Inflammation is detailed in the pathogenesis of most perinatal brain injuries, which contributes to the risk of cerebral palsy, including neonatal stroke, preterm birth, birth asphyxia, and infection [2, 3]. Systematic reviews of the clinical literature now support an association between higher levels of circulating pro-inflammatory mediators and the diagnosis of cerebral palsy, especially in prematurity [4]. However, the duration and extent of this inflammation, as well as the consequences for children with cerebral palsy, remain unclear.

Inflammation in cerebral palsy may consist in a change in the cytokine status [4]; altered immune response [5]; adaptive immune changes, including the distribution and function of T- and B-cells [6], as well as other genetic and non-genetic changes in signaling pathways [7]. Inflammation following perinatal brain injury is commonly reported to change over time, between the acute and chronic phases of injury [8]. However, persistent inflammation (i.e., inflammation lasting months to years after the primary injury phase) has been postulated to have detrimental effects on the brain and may contribute to severe forms of the disease. This is supported by the persistent inflammation hypothesis, also known as programming effects, whereby prenatal, antenatal, or neonatal pro-inflammatory cytokines induce inflammation that contributes to long-term cytokine dysregulation [9]. The study in children with an early residual stage of cerebral palsy demonstrated the relationship between the functional level on the GMFCS scale (Gross Motor Function Classification System) and some indicators of immune status.

Key words: cerebral palsy, cytokine TNF-α, spastic palsy, GMFCS.

REFERENCES

1. Plaksina A. N., Kovtun O. P., Oshkordina A. A., Shelyakin V. A. Health of children born with assisted reproductive technologies and approaches to assessing the economic potential of ART. Prakticheskaya meditsina, 2021, vol. 19, no. 2, pp. 43–50 (in Russ.).
2. Van Naarden Braun K., Doernberg N., Schieve L., Christensen D., Goodman A., Yeargin-Allsopp M. Birth prevalence of cerebral palsy: a population-based study. Pediatrics, 2016, vol. 137 (1), rr. 1–9.
3. Askie L.M., Darlow B.A., Finer N. et al. Association between oxygen saturation targeting and death or disability in extremely preterm infants in the neonatal oxygenation prospective meta-analysis collaboration. Jama, 2018, vol. 319 (21), rr. 2190–2201.
4. Sharova O., Smiyan O., Borén T. Immunological effects of cerebral palsy and rehabilitation exercises in children. Brain, Behavior, & Immunity-Health, 2021, vol. 18, r.100365.
5. Mads L. Larsen, Wiingreen R., Jensen A., Rackauskaite G., Laursen B., Hansen M. et al. The effect of gestational age on major neurodevelopmental disorders in preterm infants. Pediatric Research, 2022, vol. 91 (7), rr. 1906–1912.
6. Sudip P., Anjuman N., Mrinalini B. A review on recent advances of cerebral palsy. Oxidative Medicine and Cellular Longevity, 2022, vol. 2022, rr. 20–26.
7. Horber V. The origin of the cerebral palsies: contribution of population-based neuroimaging data. Neuropediatrics, 2020, vol. 51 (2), rr. 113–119.
8. Richard E.M., Bakhtiari S., Marsh A.P.L., Kaiyrzhanov R. et al. Bi-allelic variants in SPATA5L1 lead to intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss. American journal of human genetics, 2021, vol. 108 (10), rr. 2006–2016.
9. Friedman J.M., Van Essen P., Van Karnebeek C.D.M. Cerebral palsy and related neuromotor disorders: overview of genetic and genomic studies. Molecular genetics and metabolism, 2022, vol. 137 (4), rr. 399–419.
10. Elliott A.M., Guimond C. Genetic counseling considerations in cerebral palsy. Molecular genetics and metabolism, 2022, vol. 137 (4), rr. 428–435.
11. Hakami W.S., Hundallah K.J., Tabarki B.M. Metabolic and genetic disorders mimicking cerebral palsy. Neurosciences (Riyadh), 2019, vol. 24 (3), rr. 155–163.
12. Sokolova M.G. Neurotrophins are markers of the reparative-destructive process in the CNS in children with cerebral palsy. Vestnik Severo-Zapadnogo gosudarstvennogo meditsinskogo universiteta im. I.I. Mechnikova, 2015, vol. 7, no. 1, pp. 93–96 (in Russ.).
13. Panova M.S., Panchenko A.S. Markers of damage to the central nervous system in children. The current state of the problem. Sovremennoe sostoyanie problemy. Pediatr, 2020, vol. 11, no. 3, pp. 93–99 (in Russ.).
14. Zareen Z., Strickland T., Fallah L., McEneaney V. et al. Cytokine dysregulation in children with cerebral palsy. Developmental Medicine & Child Neurology, 2021, vol. 63 (4), pp. 407–412.
15. Lin C.Y. Altered inflammatory responses in preterm children with cerebral palsy. Annals of neurology, 2010, vol. 68 (2), pp. 204–212.
16. Cappelletti M., Presicce P., Kallapur S.G. Immunobiology of acute chorioamnionitis. Frontiers in immunology, 2020, vol. 11, p. 649.
17. Osredkar D. Apgar score and risk of cerebral palsy in preterm infants: a population-based cohort study. Neuropediatrics, 2021, vol. 52 (4), pp. 310–315.
18. Volpe J.J. Systemic inflammation, oligodendroglial maturation, and the encephalopathy of prematurity. Ann Neurol, 2011, vol. 4, rr. 50–65.
19. Douglas-Escobar M., Weiss M. D. Biomarkers of brain injury in the premature infant. Frontiers in neurology, 2013, vol. 3, p. 185.
20. Goracke-Postle C.J. Expression of and correlational patterns among neuroinflammatory, neuropeptide, and neuroendocrine molecules from cerebrospinal fluid in cerebral palsy. BMC neurology, 2021, vol. 21 (1), pp. 1–13.
21. Semenova K.A. Vosstanovitel’noe lechenie detey s perinatal’nym porazheniem nervnoy sistemy i s detskim tserebral’nym paralichom [Restorative treatment of children with perinatal lesions of the nervous system and with cerebral palsy]. Moscow: Zakon i poryadok, 2007. 616 p.
22. Kaukola T. Cerebral palsy is characterized by protein mediators in cord serum. Annals of Neurology, 2004, vol. 55 (2), pp. 186–194.
23. Goracke-Postle C.J. Expression of and correlational patterns among neuroinflammatory, neuropeptide, and neuroendocrine molecules from cerebrospinal fluid in cerebral palsy. BMC neurology, 2021, vol. 21 (1), pp. 1–13.
24. Magalhaes R.C. Inflammatory biomarkers in children with cerebral palsy: A systematic review. Research in developmental disabilities, 2019, vol. 95, p. 103508.
25. Gaynetdinova D.D., Afandieva L.Z. Method for determining the severity of cerebral palsy in young children. Patent na izobretenie no. 2013107300/15, 2015. Byulleten’ Izobreteniya poleznye modeli, no. 18 (in Russ.).
26. Kamilova T.A., Golota A.S., Vologzhanin D.A., Shneyder O.V., Shcherbak S.G. Biomarkers of cerebral palsy. Fizicheskaya i reabilitatsionnaya meditsina, meditsinskaya reabilitatsiya, 2021, vol. 3, no. 3, pp. 301–317 (in Russ.).
27. Dammann O. Persistent neuro-inflammation in cerebral palsy: a therapeutic window of opportunity? Acta paediatrica, 2007, vol. 96 (1), pp. 6–7.
28. Liguori I., Russo G., Curcio F. Oxidative stress, aging, and disease. Clinical Interventions in Aging, 2018, vol. 13, rr. 757–772.
29. Burton G.J., Jauniaux E. Oxidative stress. Best Practice and Research Clinical Obstetrics and Gynaecology, 2011, vol. 25 (3), rr. 287–299.
30. Magalhaes R.C., Moreira J.M., Lauar A.O. Inflammatory biomarkers in children with cerebral palsy: A systematic review. Developmental Disabilities Research Reviews, 2019, vol. 95, r. 103508.
31. Alpay Savasan Z., Yilmaz A., Ugur Z. Metabolomic profiling of cerebral palsy brain tissue reveals novel central biomarkers and biochemical pathways associated with the disease: a pilot study. Metabolites, 2019, vol. 9 (2), rr. 27–31.
32. Fahey M.C., Maclennan A.H., Kretzschmar D. The genetic basis of cerebral palsy. Developmental Medicine and Child Neurology, 2017, vol. 59 (5), rr. 462–469.
33. Nazmi A., Albertsson A.M., Rocha-Ferreira E., Zhang X., Vontell R., Zelco A. Lymphocytes contribute to the pathophysiology of neonatal brain injury. Frontiers in Neurology, 2018, vol. 9, r. 159.
34. Volpe J.J. The encephalopathy of prematurity — brain injury and impaired brain development inextricably intertwined. Seminars in Pediatric Neurology, 2009, vol. 16, rr. 167–178.
35. Voronina E.V. The role of tumor necrosis factor-alpha in the immunopathogenesis of diseases of various etiologies and its significance in the development of anticytokine therapy with monoclonal antibodies. Meditsinskaya immunologiya, 2018, vol. 20, no. 6, pp. 797–806 (in Russ.).
36. Schleiss M.R. Altered cytokine responses in children with cerebral palsy: pathogenesis and novel therapies. Developmental medicine and child neurology, 2021, vol. 63 (4), p. 365.
37. Dumbuya J.S. The role of G-CSF neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE): current status. Journal of Neuroinflammation, 2021, vol. 18 (1), pp. 1–15.
38. Qin X. Mechanism and treatment related to oxidative stress in neonatal hypoxic-ischemic encephalopathy. Frontiers in Molecular Neuroscience, 2019, vol. 12, r. 88.
39. Gray L., Ng H., Bartlett D. The gross motor function classification system: an update on impact and clinical utility. Pediatric Physical Therapy, 2010, vol. 22 (3), rr. 315–320.
40. Pérez-Figueroa E., Álvarez-Carrasco P., Ortega E., Maldonado-Bernal C. Neutrophils: many ways to die. Frontiers in Immunology, 2021, vol. 4, r. 631821.
41. Chesnokova N.P., Ponukalina E.V., Nevvazhay T.A., Polutova N.V., Bizenkova M.N. Morphofunctional and metabolic features of peripheral blood granulocytes. Mezhdunarodnyy zhurnal prikladnykh i fundamental’nykh issledovaniy, 2015, no. 4-2, pp. 285–289 (in Russ.).
42. Badawi N., Felix J.F., Kurinczuk J.J. Cerebral palsy following term newborn encephalopathy: a population-based study. Developmental Medicine and Child Neurology, 2005, vol. 47, rr. 293–298.
43. Sweetman D.U., Onwuneme C., Watson W.R., Murphy J.F., Molloy E.J. Perinatal asphyxia and erythropoietin and VEGF: serial serum and cerebrospinal fluid responses. Neonatology, 2017, vol. 111, rr. 253–259.
44. O’Hare F.M., Watson R.W., O’Neill A., Blanco A., Donoghue V., Molloy E.J. Persistent systemic monocyte and neutrophil activation in neonatal encephalopathy. Journal Matern Fetal Neonatal Med, 2016, vol. 29, rr. 582–589.
45. Bockhorn M., Goralski M., Prokofiev D., Dammann P., Grünewald P., Trippler M., Schlaak J.F. VEGF is important for early liver regeneration after partial hepatectomy. Journal of Surgical Research, 2007, vol. 138 (2), rr. 291–299.